# GOHIBIC (vilobelimab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vilobelimab

> The next catalyst for GOHIBIC (vilobelimab), sponsored by InflaRx N.V. (IFRX), is its interim data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for GOHIBIC (vilobelimab)?

The next catalyst for GOHIBIC (vilobelimab), sponsored by InflaRx N.V. (IFRX), is its interim data readout, 2027. Press release filed with the SEC (EX-99): "InflaRx is currently in the planning stages for this development effort, with a goal of generating initial data from these open-label proof-of-concept studies in 2027." [Calendar and source filings](https://sec-api.dev/pdufa/vilobelimab)

Source: Press release filed with the SEC (EX-99), accession 0001140361-26-031540, https://www.sec.gov/Archives/edgar/data/1708688/000114036126031540/ef20079015_ex99-3.htm (retrieved 2026-11-12). Last confirmed 2026-08-06. Cite: https://sec-api.dev/pdufa/vilobelimab#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | GOHIBIC (vilobelimab) |
| Codes |  |
| Sponsor | InflaRx N.V. (IFRX) https://sec-api.dev/companies/ifrx/catalysts |
| Indications | Pyoderma Gangrenosum |
| Modality | antibody |
| FDA designations | breakthrough, fast track, orphan |

## Timeline

### Nov 2023: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-03-20, last confirmed 2025-03-20.
- SEC Form 10-K (accession 0001213900-25-025292): "These include PG, a chronic inflammatory skin disorder for which we started a Phase 3 study with the first patient treated in November 2023, the treatment of critically ill COVID-19 patients, for which we concluded a Phase 3 study in March 2022 and subsequently were granted the EUA by the FDA in April 2023, and marketing authorization, under exceptional circumstances, by the European Commission in January 2025." https://www.sec.gov/Archives/edgar/data/1708688/000121390025025292/ea0234504-20f_inflarxnv.htm

### 2025: NDA/BLA submission

- Status: scheduled. Date confidence: year.
- First seen 2025-05-07, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017620): "We expect our expenses associated with vilobelimab to increase in 2025 compared to 2024, as we continue discussions with the FDA related to the planned submission of a BLA for full approval of" https://www.sec.gov/Archives/edgar/data/1708688/000114036125017620/ef20048286_ex99-2.htm

### May 2025: interim data readout

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-009582): "Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025" https://www.sec.gov/Archives/edgar/data/1708688/000114036125009582/ef20045567_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-009582): "Vilobelimab in PG - Pivotal Phase 3 trial interim analysis expected by the end of May 2025" https://www.sec.gov/Archives/edgar/data/1708688/000114036125009582/ef20045567_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-009582): "This is expected to enable the interim analysis for trial size adaptation or futility by the end of May 2025." https://www.sec.gov/Archives/edgar/data/1708688/000114036125009582/ef20045567_ex99-1.htm

### Jun 2025: interim data readout

- Status: scheduled. Date confidence: month. Stage: 3.
- First seen 2025-05-07, last confirmed 2025-05-07.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017620): "Vilobelimab in PG - Announcement on pivotal Phase 3 interim analysis expected at end of May to early June 2025" https://www.sec.gov/Archives/edgar/data/1708688/000114036125017620/ef20048286_ex99-3.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-25-017620): "We believe that the Phase 3 interim analysis is expected at the end of May to early June 2025." https://www.sec.gov/Archives/edgar/data/1708688/000114036125017620/ef20048286_ex99-2.htm

### July 11, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Pyoderma Gangrenosum.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05964413 (Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-07-11 (ACTUAL); Lead Sponsor InflaRx GmbH." https://clinicaltrials.gov/study/NCT05964413

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001140361-25-009582): "Topline data from this study are expected in the summer of 2025, with a goal of informing the planning and design of a larger, longer-term Phase 2b study by year-end 2025." https://www.sec.gov/Archives/edgar/data/1708688/000114036125009582/ef20045567_ex99-1.htm

### 2027: interim data readout

- Status: scheduled. Date confidence: year.
- First seen 2026-08-06, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001140361-26-031540): "InflaRx is currently in the planning stages for this development effort, with a goal of generating initial data from these open-label proof-of-concept studies in 2027." https://www.sec.gov/Archives/edgar/data/1708688/000114036126031540/ef20079015_ex99-3.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vilobelimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GOHIBIC (vilobelimab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vilobelimab

```bibtex
@misc{secapidev_pdufa_vilobelimab_20261116,
  title        = {GOHIBIC (vilobelimab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vilobelimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vilobelimab_20261116","title":"GOHIBIC (vilobelimab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vilobelimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
